The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115406 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yuchen Qi und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Stomatological Hospital of Xuzhou Medical University, Xuzhou 221000, China; School of Stomatology, Xuzhou Medical University, Xuzhou 2…. Hauptthemen laut MEDLINE: p21-Activated Kinases, Mouth Neoplasms, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Xuzhou Science and Technology Program.
Abstract (Originalsprache)
OBJECTIVES: Despite the established clinical link between PAK5 and cancer progression, its biological role in oral squamous cell carcinoma (OSCC) remains unclear. This study aims to clarify the relationship between PAK5 and OSCC. The immunosuppressive tumor microenvironment (TME) is a key contributor to intrinsic resistance to immunotherapy. Identifying molecules that modulate this TME is crucial for overcoming such resistance. Here, we investigate PAK5's role in immunotherapy resistance by PAK5 inhibitors combined with pembrolizumab treatment, evaluating PAK5 as a therapeutic target and advancing combination therapies to tackle drug resistance in OSCC immunotherapy. METHODS: Bioinformatics analysis and clinical sampling were utilized to characterize the relationship between PAK5 and OSCC. The effects of PAK5 on OSCC cell proliferation, migration, and invasion were assessed using the CCK-8, colony formation, wound-healing, and Transwell assays, respectively. In vivo, xenograft tumor model was established to evaluate therapeutic efficacy by monitoring post-treatment tumor volume and weight. Drug safety was assessed via H&E staining. Western blotting, immunofluorescence, and ELISA were employed to elucidate the underlying mechanisms. RESULTS: PAK5 is overexpressed in OSCC and contributes to the proliferation, migration, and invasion of OSCC cells. Animal studies demonstrated that the combination of a PAK5 small-molecule inhibitor and pembrolizumab treatment exhibited superior therapeutic efficacy, with significant reductions in tumor volume and weight. Mechanistically, this combinatorial treatment effectively alleviating immunosuppression and remodeling the tumor microenvironment (TME). CONCLUSIONS: This study has developed new targets for the treatment of OSCC and provided new ideas for clinical exploration of immunotherapy resistance. CLINICAL SIGNIFICANCE: PAK5 may serve as a novel therapeutic target and a promising candidate for combination therapy in clinical development to address the challenge of drug resistance in immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Stomatological Hospital of Xuzhou Medical University, Xuzhou 221000, China; School of Stomatology, Xuzhou Medical University, Xuzhou 221000, China. Electronic address: 302105120683@stu.xzhmu.edu.cn.
- Xuzhou Medical University School of Pharmacy, Xuzhou 221000, China.
- Jiangsu University Affiliated Jingjiang People's Hospital, China.
- The Affiliated Stomatological Hospital of Xuzhou Medical University, Xuzhou 221000, China.
- School of Stomatology, Xuzhou Medical University, Xuzhou 221000, China.
- The Affiliated Stomatological Hospital of Xuzhou Medical University, Xuzhou 221000, China; School of Stomatology, Xuzhou Medical University, Xuzhou 221000, China. Electronic address: 17852063773@163.com.
Förderung
- Xuzhou Science and Technology Program
Zitieren
APA
Qi, Y., Mou, J., Huang, J., Li, T., Leng, C., & Si, Y. (2025). The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115406
Vancouver
Qi Y, Mou J, Huang J, Li T, Leng C, Si Y. The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115406
BibTeX
@article{Qi2025,
author = {Qi, Yuchen and Mou, Jie and Huang, Jiadong and Li, Tianyi and Leng, Chunru and Si, Yameng},
title = {The role and mechanism of PAK5 in the development and immunotherapy of oral squamous cell carcinoma},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115406}
}
EUVIMED